Enveda, a biotech startup that applies artificial intelligence to discover drug candidates in the natural world, has closed a $311 million Series E round at a $2 billion valuation. The financing was led by Catalio Capital Management, with participation from Iconiq and other investors. The new funding doubles Enveda’s valuation compared with 12 months ago.
Concept and founding
Enveda’s approach is to mine plants and microbes for molecules that can serve as drugs or drug leads, rather than relying solely on de novo chemical synthesis in the lab. Viswa Colluru founded Enveda in 2019; he was an early employee at Recursion Pharmaceuticals. The company uses machine learning and related techniques to accelerate discovery of therapeutic candidates derived from natural sources.
Clinical progress
Although no FDA-approved drugs to date have been credited to AI-based discovery, Enveda is among the companies advancing AI-identified candidates into human testing. The startup is currently running clinical studies of several drug candidates, including one aimed at severe skin conditions and another intended to help maintain weight loss after discontinuing GLP-1 therapies.
Why this matters
The $311 million injection should help Enveda scale its clinical programs and broaden evaluation of natural-product-derived candidates. The financing reflects investor interest in combining AI discovery methods with natural product chemistry, but definitive therapeutic impact will depend on outcomes from the ongoing human trials and subsequent regulatory reviews.
Investors and financial context
Catalio Capital Management led the Series E, joined by Iconiq and other participants. The round raised Enveda’s valuation to $2 billion, effectively doubling the company’s value compared with a year earlier.
Summary
Since its 2019 founding, Enveda has focused on coupling AI with natural product discovery and now has secured significant funding to advance multiple clinical-stage programs. Final proof of benefit will require successful clinical outcomes and regulatory approvals.
